These novel data overall point to a potential role of ENO1 in recruiting immune pathways, particularly in triple-negative breast carcinomas and advanced disease, immediately suggesting that there may be a role for ENO1-targeted therapy as an adjunct to immune therapy. Here, ENO1 is linked to triple-negative breast carcinoma.